Successful treatment of JAK1-associated inflammatory disease
Journal of Allergy and Clinical Immunology · 2023-10 · 152 (4) · 972-983
DOI: 10.1016/j.jaci.2023.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-10. Verfasst von Antoine Fayand und 34 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique (CNRS), Paris, France; Departm…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Dermatitis, Atopic, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Centre National de la Recherche Scientifique, Institut Pasteur, ANR.
Abstract (Originalsprache)
BACKGROUND: Gain-of-function variants of JAK1 drive a rare immune dysregulation syndrome associated with atopic dermatitis, allergy, and eosinophilia. OBJECTIVES: This study sought to describe the clinical and immunological characteristics associated with a new gain-of-function variant of JAK1 and report the therapeutic efficacy of Janus kinase (JAK) inhibition. METHODS: The investigators identified a family affected by JAK1-associated autoinflammatory disease and performed clinical assessment and immunological monitoring on 9 patients. JAK1 signaling was studied by flow and mass cytometry in patients' cells at basal state or after immune stimulation. A molecular disease signature in the blood was studied at the transcriptomic level. Patients were treated with 1 of 2 JAK inhibitors: either baricitinib or upadacitinib. Clinical, cellular, and molecular response were evaluated over a 2-year period. RESULTS: Affected individuals displayed a syndromic disease with prominent allergy including atopic dermatitis, ichthyosis, arthralgia, chronic diarrhea, disseminated calcifying fibrous tumors, and elevated whole blood histamine levels. A variant of JAK1 localized in the pseudokinase domain was identified in all 9 affected, tested patients. Hyper-phosphorylation of STAT3 was found in 5 of 6 patients tested. Treatment of patients' cells with baricitinib controlled most of the atypical hyper-phosphorylation of STAT3. Administration of baricitinib to patients led to rapid improvement of the disease in all adults and was associated with reduction of systemic inflammation. CONCLUSIONS: Patients with this new JAK1 gain-of-function pathogenic variant displayed very high levels of blood histamine and showed a variable combination of atopy with articular and gastrointestinal manifestations as well as calcifying fibrous tumors. The disease, which appears to be linked to STAT3 hyperactivation, was well controlled under treatment by JAK inhibitors in adult patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Centre National de la Recherche Scientifique (CNRS), Paris, France; Department of Internal Medicine, Tenon Hospital, Assistance Publique-Hôpitaux…
- Pediatric Infectious Disease Group, Créteil, France; Department General Pediatrics, Centre Hospitalier de Versailles, Le Chesnay, France.
- Translational Immunology Unit, Institut Pasteur, Université de Paris Cité, Paris, France.
- Genetic Laboratory, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; Department of Internal Medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), So…
- Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (APHP), Université de Paris Cité, Paris, France.
- Department of Pathology, Sorbonne Université, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Förderung
- Centre National de la Recherche Scientifique
- Institut Pasteur
- ANR
- Institut National de la Santé et de la Recherche Médicale
Zitieren
APA
Fayand, A., Hentgen, V., Posseme, C., Lacout, C., Picard, C., Moguelet, P., Cescato, M., Sbeih, N., Moreau, T. R. J., Zhu, Y. Y. J., Charuel, J. L., Corneau, A., Deibener-Kaminsky, J., Dupuy, S., Fusaro, M., Hoareau, B., Hovnanian, A., Langlois, V., Le Corre, L., …, & Georgin-Lavialle, S. (2023). Successful treatment of JAK1-associated inflammatory disease. Journal of Allergy and Clinical Immunology, 152(4), 972-983. https://doi.org/10.1016/j.jaci.2023.06.004
Vancouver
Fayand A, Hentgen V, Posseme C, Lacout C, Picard C, Moguelet P, et al. Successful treatment of JAK1-associated inflammatory disease. Journal of Allergy and Clinical Immunology. 2023;152(4):972-983. doi:10.1016/j.jaci.2023.06.004
BibTeX
@article{Fayand2023,
author = {Fayand, Antoine and Hentgen, Véronique and Posseme, Céline and Lacout, Carole and Picard, Capucine and Moguelet, Philippe and Cescato, Margaux and Sbeih, Nabiha and Moreau, Thomas R J and Zhu, Yixiang Y J and Charuel, Jean-Luc and Corneau, Aurélien and Deibener-Kaminsky, Joelle and Dupuy, Stéphanie and Fusaro, Mathieu and Hoareau, Benedicte and Hovnanian, Alain and Langlois, Vincent and Le Corre, Laurent and Maciel, Thiago T and Miskinyte, Snaigune and Miyara, Makoto and Moulinet, Thomas and Perret, Magali and Schuhmacher, Marie Hélène and Rignault-Bricard, Rachel and Viel, Sébastien and Vinit, Angélique and Soria, Angèle and Duffy, Darragh and Launay, Jean-Marie and Callebert, Jacques and Herbeuval, Jean Philippe and Rodero, Mathieu P and Georgin-Lavialle, Sophie},
title = {Successful treatment of JAK1-associated inflammatory disease},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {4},
pages = {972--983},
doi = {10.1016/j.jaci.2023.06.004}
}
EUVIMED